Slide 1: Result presentation Q2/2021
5 August 2021, Seppo Kopsala, CEO / Lars Lindqvist, CFO Result presentation Q2/2021
Slide 2: Highlights
Highlights OPT@MED
Slide 3: Highlights Q2-2021
Very strong growth: Revenue increased 55%. Software growth was 21% and 1. Devices 124% against a weak Covid-19 affected comparison period Highlights Q2-2021 Sinopharm-Phoebus: cooperation started in Q1 and continues, and it is 2. currently driving our growth in China Favourable megatrends continue:
Slide 4: Focus areas
Focus areas China: • The Sinopharm-Phoebus deliveries continued to increase • Training of the regional sales organizations have started • Currently it is hard to forecast revenue for H2-2021 in China and the long-term potential can only be assessed after 12-18 months USA: • Direct sales performing w
Slide 5: COVID-19 Coronavirus
COVID-19 Coronavirus • Delta variant spreading; vaccinations progressing • What does it mean to Optomed: • The Software segment is performing well due to the recurring revenue model • The travel restrictions continue to slow down the global screening solution sales • Device segment’s traditional mar
Slide 6: Q2/2021 Financial highlights (KEUR)
Q2/2021 Financial highlights (KEUR) Q2/2021 Q2/2020 Change Revenue 4,012 2,597 54.5% Gross profit 1) 3,324 1,907 74.3% Gross margin 2) 82.9% 73.4% 9.5 bps Adjusted EBITDA 177 -325 154.5% Adjusted EBITDA margin 4.4% -12.5% 16.9 bps Net profit/ loss -864 -976 11.5% Earnings per share -0.06 -0.08 22.5%
Slide 7: H1/2021 Financial highlights (KEUR)
H1/2021 Financial highlights (KEUR) H1/2021 H1/2020 Change Revenue 7,956 5,631 41.3% Gross profit 1) 5,901 3,884 51.9% Gross margin 2) 74,2% 69.0% 5.2 bps Adjusted EBITDA -138 -900 84.7% Adjusted EBITDA margin -1.7% -16.0% 14.3 bps Net profit/ loss -1,480 -2,226 33.5% Earnings per share -0.11 -0.19
Slide 8: Devices segment highlights
Devices segment highlights OPT@MED
Slide 9: Devices segment highlights
Revenue grew by 123.5% mainly Q2/2021 Q2/2020 Change driven by solid performance in 1. China, but also other key markets Devices segment highlights and sales channels showed good Revenue 1,896 848 123.5% progress Disposable eye cups for handheld Gross profit 1,811 543 233.2% cameras and two traditio
Slide 10: Software segment highlights
Software segment highlights
Slide 11: Software segment highlights
The Software segment continued Q2/2021 Q2/2020 Change its solid performance recurring 1. business. Global screening Software segment highlights solution projects progressed in 2,116 1,749 21.0% Revenue Asia and the Middle-East Optomed was selected as a Gross profit 1,513 1,363 11.0% 2. partner to de
Slide 12: Outlook 2021
Outlook 2021
Slide 13: Outlook 2021
Outlook 2021 Optomed expects its full year 2021 revenue to grow strongly compared to 2020 (Announced 8 April 2021)
Slide 14: Financial targets
Financial targets Revenue Growth Adjusted EBITDA Optomed’s medium-term target is to deliver Optomed’s target is to prioritise a double-digit annual organic revenue investments in the organisation to growth. In the long-term Optomed’s target support growth in the medium-term and is to deliver an aver
Slide 15: Balance sheet
Balance sheet 30 June 2021 30 June 2020 Balance sheet ASSETS Goodwill 4,256 4,256 Development costs 5,531 5,273 • Equity ratio of 64.5 (66.0) percent Other intangible assets 2,635 2,999 Total intangible assets 12,422 12,528 • Total borrowings of EUR 5.8 (6.6) Total tangible assets 1,352 1,259 millio
Slide 16: Cash flow
Cash flow Q2 2021 Q2 2020 Loss for the financial year -864 -976 Cash flows before change -253 -254 in net working capital Change in net working capital -1,112 393 • Cash flow from operating activities amounted to EUR -1,4 (0.1) million Cash flows before finance items -1,365 139 Cash flows from finan
Slide 17: Optomed's mission is to prevent blindness
“ Optomed’s Expansion into new geographical markets mission is to prevent blindness by improving access to eye screening Opening new customer segments: primary care globally Bringing AI-integrated health screening to the market
Slide 18: Appendix
Appendix
Slide 19: Devices Segment H1/2021 financials
Devices Segment H1/2021 financials H1/2021 H1/2020 Change % Revenue 3,343 1,822 83.4% Gross profit 2,653 940 182.4% Gross margin 79.4% 51.6% 27.8 bps EBITDA 362 -542 166.9% EBITDA margin 10.8% -29.7% 40.5 bps
Slide 20: Software Segment H1/2021 financials
Software Segment H1/2021 financials H1/2021 H1/2020 Change % Revenue 4,613 3,809 21.1% Gross profit 3,248 2,944 10.3% Gross margin 70.4% 77.3% -6.9 bps EBITDA 788 847 -6.9% EBITDA margin 17.1% 22.2% -5.1 bps
Slide 21: Cash flow H1/2021
Cash flow H1/2021 H1 2021 H1 2020 Loss for the financial year -1,480 -2,226 Cash flows before change in net working capital -465 -763 Change in net working capital -1,157 -1,819 Cash flows before finance items -1,622 -2,582 Cash flows from finance items -37 -232 Net cash from operating activities -1